CRISPR director awarded 13,000 stock options
CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares.
Rhea-AI Filing Summary
CRISPR Therapeutics AG director Ali Behbahani received a new stock option grant covering 13,000 common shares. The options have an exercise price of $51.84 per share and expire on June 5, 2036. They were awarded as compensation rather than bought on the open market.
According to the vesting terms, the options vest in 12 equal monthly installments, with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual meeting.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 13,000 shares
Grant/Award
1 txn
Insider
Behbahani Ali
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct)
Footnotes (1)
- F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Key Figures
Options granted: 13,000 options
Exercise price: $51.84 per share
Expiration date: June 5, 2036
+1 more
4 metrics
Options granted
13,000 options
Stock Option (Right to Buy) grant to director Ali Behbahani
Exercise price
$51.84 per share
Exercise price of stock options on CRISPR Therapeutics common shares
Expiration date
June 5, 2036
Option expiration for Ali Behbahani’s grant
Vesting start date
June 30, 2026
First of 12 equal monthly vesting installments
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "51.8400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"the options will vest and become exercisable in 12 equal monthly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Annual Meeting financial
"the last installment vests on the earlier of ... the date of the 2027 Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CRISPR Therapeutics (CRSP) disclose about Ali Behbahani in this Form 4?
CRISPR Therapeutics reported that director Ali Behbahani received a grant of stock options for 13,000 common shares. These options are compensation-related awards, not open-market purchases or sales, and represent his reported derivative holdings following the transaction.
How many CRISPR Therapeutics (CRSP) stock options were granted to Ali Behbahani?
Ali Behbahani was granted stock options on 13,000 CRISPR Therapeutics common shares. The filing states this full amount as his total derivative holdings after the transaction, indicating the award created a new option position rather than modifying an existing one.
What is the exercise price and expiration date of Ali Behbahani’s CRSP options?
The options granted to Ali Behbahani have an exercise price of $51.84 per share and expire on June 5, 2036. This means he may choose to buy shares at $51.84 any time after vesting and before the June 2036 expiration date.
How do Ali Behbahani’s CRISPR Therapeutics options vest over time?
The options vest in 12 equal monthly installments, subject to continued service. The first installment vests on June 30, 2026, and the last vests on the earlier of the one-year anniversary of grant or the date of CRISPR Therapeutics’ 2027 annual meeting.
Is Ali Behbahani’s CRISPR Therapeutics Form 4 transaction routine compensation?
The transaction is categorized as a grant, award, or other acquisition of options, which is typically part of director compensation. The options vest monthly over about a year, aligning with common equity-based incentive structures for board members at public companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
